The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignDerek C. Angus, Steven Webb, Paul J. Young et al.|Annals of the American Thoracic Society|2020Cited by 449
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term OutcomesKristine Broglio, Donald A. Berry, Melanie Quintana et al.|JAMA Oncology|2016Cited by 375
Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trialsScott Berry, Donald A. Berry, Kristine Broglio et al.|Clinical Trials|2013Cited by 229
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trialDavid Cella, Robert J. Motzer, Viktor Grünwald et al.|The Lancet Oncology|2016Cited by 219
Not Too Big, Not Too Small: A Goldilocks Approach To Sample Size SelectionKristine Broglio, Scott Berry, Jason T. Connor|Journal of Biopharmaceutical Statistics|2014Cited by 74